- Home
- TNXP vs KNOP Comparison
TNXP vs KNOP Comparison
Compare TNXP & KNOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- KNOP
- Stock Information
- Founded
- TNXP 2007
- KNOP 2013
- Country
- TNXP United States
- KNOP United Kingdom
- Employees
- TNXP N/A
- KNOP N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- KNOP Marine Transportation
- Sector
- TNXP Health Care
- KNOP Consumer Discretionary
- Exchange
- TNXP Nasdaq
- KNOP Nasdaq
- Market Cap
- TNXP 272.0M
- KNOP 254.2M
- IPO Year
- TNXP N/A
- KNOP 2013
- Fundamental
- Price
- TNXP $35.48
- KNOP $6.86
- Analyst Decision
- TNXP Strong Buy
- KNOP
- Analyst Count
- TNXP 2
- KNOP 0
- Target Price
- TNXP $585.00
- KNOP N/A
- AVG Volume (30 Days)
- TNXP 729.5K
- KNOP 58.1K
- Earning Date
- TNXP 08-15-2025
- KNOP 09-02-2025
- Dividend Yield
- TNXP N/A
- KNOP 1.52%
- EPS Growth
- TNXP N/A
- KNOP N/A
- EPS
- TNXP N/A
- KNOP 0.19
- Revenue
- TNXP $10,041,000.00
- KNOP $320,026,000.00
- Revenue This Year
- TNXP $11.66
- KNOP $6.77
- Revenue Next Year
- TNXP $793.18
- KNOP $0.81
- P/E Ratio
- TNXP N/A
- KNOP $36.38
- Revenue Growth
- TNXP N/A
- KNOP 8.76
- 52 Week Low
- TNXP $6.76
- KNOP $5.28
- 52 Week High
- TNXP $130.00
- KNOP $8.53
- Technical
- Relative Strength Index (RSI)
- TNXP 52.96
- KNOP 59.67
- Support Level
- TNXP $33.71
- KNOP $6.29
- Resistance Level
- TNXP $38.13
- KNOP $6.75
- Average True Range (ATR)
- TNXP 2.62
- KNOP 0.25
- MACD
- TNXP -0.44
- KNOP 0.01
- Stochastic Oscillator
- TNXP 61.01
- KNOP 82.35
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.